Compare · BSX vs SNWV
BSX vs SNWV
Side-by-side comparison of Boston Scientific Corporation (BSX) and SANUWAVE Health Inc. (SNWV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and SNWV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $63.25B, about 4299.7x SNWV ($14.7M).
- BSX has been more active in the news (14 items in the past 4 weeks vs 7 for SNWV).
- BSX has more recent analyst coverage (25 ratings vs 2 for SNWV).
- Company
- Boston Scientific Corporation
- SANUWAVE Health Inc.
- Price
- -
- -
- Market cap
- $63.25B
- $14.7M
- 1M return
- -3.39%
- -
- 1Y return
- -55.66%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 14
- 7
- Recent ratings
- 25
- 2
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- SEC Form 424B5 filed by Boston Scientific Corporation
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- Chairman, President & CEO Mahoney Michael F received a gift of 252,241 shares (SEC Form 4)
- SVP, Chief HR Officer O'Sullivan Miriam converted options into 3,871 shares and covered exercise/tax liability with 1,872 shares, increasing direct ownership by 11% to 19,565 units (SEC Form 4)
- Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
- SEC Form 10-Q filed by Boston Scientific Corporation
- SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
- Boston Scientific downgraded by TD Cowen with a new price target
- Penumbra, Inc. Reports Third Quarter 2026 Financial Results
- Boston Scientific downgraded by Oppenheimer
Latest SNWV
- Amendment: SEC Form SCHEDULE 13G/A filed by SANUWAVE Health Inc.
- SANUWAVE Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Sanuwave Announces Q3 FY2026 Financial Results
- SEC Form 10-Q filed by SANUWAVE Health Inc.
- Sanuwave Will Host a Conference Call on November 11, 2026 at 8:30 AM (ET) to Present Q3 2026 Financial Results
- Sanuwave Health Comments on 2027 Medicare Physician Fee Schedule Rate for Ultramist
- SEC Form 8-K filed by SANUWAVE Health Inc.
- SEC Form 4 filed by Director Tyler James
- SEC Form 4 filed by Chief Executive Officer Frank Morgan C.
- SEC Form 4 filed by Director Bazar Gregory Matthew